ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $116,104,000 | +38.1% | 674,636 | +0.7% | 0.02% | +33.3% |
| Q2 2021 | $84,055,000 | -5.4% | 669,821 | +2.2% | 0.01% | -14.3% |
| Q1 2021 | $88,848,000 | +9.6% | 655,176 | +3.4% | 0.01% | 0.0% |
| Q4 2020 | $81,059,000 | +21.5% | 633,575 | +6.9% | 0.01% | +7.7% |
| Q3 2020 | $66,702,000 | +25.5% | 592,749 | +6.2% | 0.01% | +18.2% |
| Q2 2020 | $53,158,000 | -13.4% | 557,980 | -18.3% | 0.01% | -31.2% |
| Q1 2020 | $61,367,000 | -9.5% | 682,845 | -46.6% | 0.02% | +128.6% |
| Q4 2019 | $67,846,000 | +179.0% | 1,279,668 | +107.9% | 0.01% | +16.7% |
| Q3 2019 | $24,314,000 | -1.2% | 615,411 | +2.8% | 0.01% | 0.0% |
| Q2 2019 | $24,599,000 | -2.4% | 598,818 | +10.6% | 0.01% | -14.3% |
| Q1 2019 | $25,207,000 | -36.2% | 541,282 | -40.3% | 0.01% | +16.7% |
| Q4 2018 | $39,496,000 | +64.0% | 906,926 | +115.5% | 0.01% | -14.3% |
| Q3 2018 | $24,090,000 | +24.1% | 420,942 | +5.2% | 0.01% | +16.7% |
| Q2 2018 | $19,406,000 | +35.9% | 399,975 | +9.5% | 0.01% | +20.0% |
| Q1 2018 | $14,284,000 | -4.0% | 365,338 | +4.3% | 0.01% | 0.0% |
| Q4 2017 | $14,872,000 | +23.4% | 350,432 | +8.5% | 0.01% | +25.0% |
| Q3 2017 | $12,048,000 | +34.8% | 322,834 | +9.8% | 0.00% | 0.0% |
| Q2 2017 | $8,939,000 | +24.4% | 294,145 | +8.4% | 0.00% | +33.3% |
| Q1 2017 | $7,185,000 | +6.6% | 271,440 | +2.8% | 0.00% | 0.0% |
| Q4 2016 | $6,738,000 | -28.5% | 264,062 | +1.4% | 0.00% | -40.0% |
| Q3 2016 | $9,423,000 | +12.6% | 260,382 | +5.7% | 0.01% | 0.0% |
| Q2 2016 | $8,371,000 | +33.7% | 246,359 | +3.8% | 0.01% | +66.7% |
| Q1 2016 | $6,260,000 | -39.5% | 237,228 | +11.8% | 0.00% | -50.0% |
| Q4 2015 | $10,348,000 | +108.1% | 212,225 | +6.2% | 0.01% | +100.0% |
| Q3 2015 | $4,973,000 | +102.6% | 199,744 | +157.4% | 0.00% | +200.0% |
| Q2 2015 | $2,455,000 | -6.8% | 77,600 | +12.1% | 0.00% | -50.0% |
| Q1 2015 | $2,635,000 | +0.5% | 69,242 | +2.8% | 0.00% | 0.0% |
| Q4 2014 | $2,623,000 | +32.7% | 67,351 | +3.0% | 0.00% | +100.0% |
| Q3 2014 | $1,977,000 | +2.0% | 65,400 | +14.6% | 0.00% | 0.0% |
| Q2 2014 | $1,938,000 | +11.6% | 57,054 | +13.4% | 0.00% | 0.0% |
| Q1 2014 | $1,736,000 | +32.4% | 50,333 | +52.0% | 0.00% | 0.0% |
| Q4 2013 | $1,311,000 | – | 33,121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |